Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

However, hope may be on the horizon as a radical new drug has potential to be released if it passes all trials. Lenacapavir, ...

Adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV, according ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

In the general population, frailty is an aging-related risk factor for poor outcomes; individuals experiencing frailty face ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV, according ...

Without public health surveillance, officials trying to tackle outbreaks, identify threats and evaluate treatments are working ‘in the darkness of ignorance.’ ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...

Feb. 18, 2025 — Viruses, like those that cause COVID-19 or HIV, are formidable opponents once they invade our bodies. Antiviral treatments strive to block a virus or halt its replication.

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

# Dr Forbes outlined the symptoms of common STIs, emphasising that some people may have no symptoms, making regular screening essential. Chlamydia symptoms include pain during urination, abnormal ...